Oral squamous cell carcinoma (OSCC) is the third most common tumor in the cat (10% of all tumors) and represents 61% of the tumors in the mouth. Generally, this devastating disease is recognized late in its course and quickly becomes debilitating with survival times of only about 3 months. The location of the tumor combined with the pain it causes prevents the cat from eating, swallowing or grooming. Often feeding tubes are placed and aggressive pain management is required to help maintain basic quality of life and prolong survival. To date, there is no reliable or durable therapy available to treat this disease and, despite efforts, there has been no improvement in quality of life or survival times for these cats. Novel targeted therapies, histone deacetylase (HDAC) inhibitors, have been shown to inhibit growth and kill human OSCC and various canine cancer cells. As a result, the researcher will investigate the response of feline OSCC cell lines to novel targeted therapies in order to determine whether they could be considered for treatment of OSCC in cats to improve survival.